Arovella Therapeutics Ltd
ASX:ALA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
M
|
Midland Ic&I Ltd
HKEX:459
|
HK |
|
T
|
Tianjin TEDA Co Ltd
SZSE:000652
|
CN |
|
eBook Initiative Japan Co Ltd
TSE:3658
|
JP |
|
A
|
Atlas Cycles (Haryana) Ltd
NSE:ATLASCYCLE
|
IN |
|
Preformed Line Products Co
NASDAQ:PLPC
|
US |
|
F
|
Fortnox AB
LSE:0G3T
|
SE |
|
M
|
Marmaris Altinyunus Turistik Tesisleri AS
IST:MAALT.E
|
TR |
|
Changan Minsheng APLL Logistics Co Ltd
HKEX:1292
|
CN |
|
T
|
Tencent Holdings Ltd
OTC:TCTZF
|
CN |
|
Ningbo Shimao Energy Co Ltd
SSE:605028
|
CN |
|
V
|
VINX Corp
TSE:3784
|
JP |
|
Senco Gold Ltd
NSE:SENCO
|
IN |
|
S
|
Sanoma Oyj
OMXH:SANOMA
|
FI |
|
L
|
Lypsa Gems & Jewellery Ltd
NSE:LYPSAGEMS
|
IN |
|
Giantplus Technology Co Ltd
TWSE:8105
|
TW |
Arovella Therapeutics Ltd
Total Current Liabilities
Arovella Therapeutics Ltd
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Arovella Therapeutics Ltd
ASX:ALA
|
Total Current Liabilities
AU$1.5m
|
CAGR 3-Years
0%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
|
Recce Pharmaceuticals Ltd
ASX:RCE
|
Total Current Liabilities
AU$11.4m
|
CAGR 3-Years
114%
|
CAGR 5-Years
55%
|
CAGR 10-Years
N/A
|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Total Current Liabilities
AU$261m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Total Current Liabilities
AU$4.3m
|
CAGR 3-Years
37%
|
CAGR 5-Years
42%
|
CAGR 10-Years
6%
|
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Total Current Liabilities
AU$10.4m
|
CAGR 3-Years
11%
|
CAGR 5-Years
61%
|
CAGR 10-Years
N/A
|
|
|
Nyrada Inc
ASX:NYR
|
Total Current Liabilities
AU$545.6k
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
Arovella Therapeutics Ltd
Glance View
Arovella Therapeutics Ltd. develops pharmaceuticals and distributes medical devices and consumables. The company is headquartered in Perth, Western Australia. The company went IPO on 2002-01-24. The firm focuses on specific disease areas, oncology and conditions that affect the central nervous system. The company is focused on developing therapies to treat human disease. The firm is developing its invariant natural killer T (iNKT) cell therapy platform to treat blood cancers. The firm's OroMist technology develops oral sprays to reformulate pharmaceuticals. Its ZolpiMist oral spray formulation of zolpidem tartrate to treat short-term insomnia. The company is also developing oral sprays to treat migraine headaches, motion sickness, and drug-resistant epilepsy.
See Also
What is Arovella Therapeutics Ltd's Total Current Liabilities?
Total Current Liabilities
1.5m
AUD
Based on the financial report for Jun 30, 2025, Arovella Therapeutics Ltd's Total Current Liabilities amounts to 1.5m AUD.
What is Arovella Therapeutics Ltd's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
-6%
Over the last year, the Total Current Liabilities growth was -27%.
